izpis_h1_title_alt

The effectiveness of calcium electroporation combined with gene electrotransfer of a plasmid encoding IL-12 is tumor type-dependent
ID Lisec, Barbara (Avtor), ID Markelc, Boštjan (Avtor), ID Uršič Valentinuzzi, Katja (Avtor), ID Serša, Gregor (Avtor), ID Čemažar, Maja (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (58,49 MB)
MD5: 57D31E1AB62B3F4A16145A904FBF1D5C
URLURL - Izvorni URL, za dostop obiščite https://www.frontiersin.org/articles/10.3389/fimmu.2023.1189960/full Povezava se odpre v novem oknu

Izvleček
Introduction: In calcium electroporation (CaEP), electroporation enables the cellular uptake of supraphysiological concentrations of Ca$^{2+}$, causing the induction of cell death. The effectiveness of CaEP has already been evaluated in clinical trials; however, confirmatory preclinical studies are still needed to further elucidate its effectiveness and underlying mechanisms. Here, we tested and compared its efficiency on two different tumor models to electrochemotherapy (ECT) and in combination with gene electrotransfer (GET) of a plasmid encoding interleukin-12 (IL-12). We hypothesized that IL-12 potentiates the antitumor effect of local ablative therapies as CaEP and ECT. Methods: The effect of CaEP was tested in vitro as well as in vivo in murine melanoma B16-F10 and murine mammary carcinoma 4T1 in comparison to ECT with bleomycin. Specifically, the treatment efficacy of CaEP with increasing calcium concentrations alone or in combination with IL-12 GET in different treatment protocols was investigated. We closely examined the tumor microenvironment by immunofluorescence staining of immune cells, as well as blood vessels and proliferating cells. Results: In vitro, CaEP and ECT with bleomycin reduced cell viability in a dose-dependent manner. We observed no differences in sensitivity between the two cell lines. A dose-dependent response was also observed in vivo; however, the efficacy was better in 4T1 tumors than in B16-F10 tumors. In 4T1 tumors, CaEP with 250 mM Ca resulted in more than 30 days of growth delay, which was comparable to ECT with bleomycin. In contrast, adjuvant peritumoral application of IL-12 GET after CaEP prolonged the survival of B16-F10, but not 4T1-bearing mice. Moreover, CaEP with peritumoral IL-12 GET modified tumor immune cell populations and tumor vasculature. Conclusions: Mice bearing 4T1 tumors responded better to CaEP in vivo than mice bearing B16-F10 tumors, even though a similar response was observed in vitro. Namely, one of the most important factors might be involvement of the immune system. This was confirmed by the combination of CaEP or ECT with IL-12 GET, which further enhanced antitumor effectiveness. However, the potentiation of CaEP effectiveness was also highly dependent on tumor type; it was more pronounced in poorly immunogenic B16-F10 tumors compared to moderately immunogenic 4T1 tumors.

Jezik:Angleški jezik
Ključne besede:electroporation, electrochemotherapy, ECT, gene electrotransfer, GET, interleukin 12, IL12, calcium electroporation, murine tumor models, bleomycin, BLM, calcium
Vrsta gradiva:Članek v reviji
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:ZF - Zdravstvena fakulteta
BF - Biotehniška fakulteta
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2023
Št. strani:17 str.
Številčenje:Vol. 14, art. 1189960
PID:20.500.12556/RUL-155260 Povezava se odpre v novem oknu
UDK:602
ISSN pri članku:1664-3224
DOI:10.3389/fimmu.2023.1189960 Povezava se odpre v novem oknu
COBISS.SI-ID:153686531 Povezava se odpre v novem oknu
Datum objave v RUL:22.03.2024
Število ogledov:774
Število prenosov:59
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Frontiers in immunology
Skrajšan naslov:Front. immunol.
Založnik:Frontiers Research Foundation
ISSN:1664-3224
COBISS.SI-ID:30774233 Povezava se odpre v novem oknu

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:elektroporacija, elektrokemoterapija, genski elektroprenos, interlevkin 12

Projekti

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:P3-0003
Naslov:Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:J3-2528
Naslov:Imunski genski elektroprenos IL-12 in IL-2 za zdravljenje imunološko hladnih/vročih tumorjev

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:Z3-2651
Naslov:Elektrokemoterapija kot in situ vakcinacija

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:J3-8202
Naslov:Spremljanje imunskega odziva v realnem času po in situ vakcinaciji z elektrokemoterapijo in pridruženo gensko terapijo z interlevkinom-12

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj